Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2025 results , with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was ...
In the latest quarter, 4 analysts provided ratings for Omnicell (NASDAQ:OMCL), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...
Hosted on MSN
Omnicell (NASDAQ:OMCL) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations
Healthcare tech company Omnicell (NASDAQ:OMCL) announced in Q2 CY2025, with sales up 5% year on year to $290.6 million. On top of that, next quarter’s revenue guidance ($295 million at the midpoint) ...
Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas--(BUSINESS WIRE)-- Omnicell, Inc. (“Omnicell,” “we,” “our ...
Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, ...
FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Omnicell Inc. (OMCL) on Tuesday reported a loss of $7 million in its first quarter. On a per-share basis, the Fort Worth, Texas-based company said it ...
FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Omnicell Inc. (OMCL) on Thursday reported third-quarter profit of $5.5 million. On a per-share basis, the Fort Worth, Texas-based company said it had ...
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results